Evolution of systemic therapy of advanced hepatocellular carcinoma
Open Access
- 1 January 2008
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (42), 6437-6441
- https://doi.org/10.3748/wjg.14.6437
Abstract
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC.Keywords
This publication has 49 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor CharacteristicsDigestive Surgery, 2008
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trialBritish Journal of Cancer, 2007
- Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or DoxorubicinJournal of Clinical Oncology, 2007
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2005
- A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular CarcinomaThe Oncologist, 2005
- Tamoxifen for hepatocellular carcinomaCochrane Database of Systematic Reviews, 2004
- Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patientsGastroenterology, 1995
- Sex hormone receptors in hepatocellular carcinoma: Is there a rationale for hormonal treatment?Journal of Hepatology, 1993